Bharat Immunologicals and Biologicals Corporation

From Bharatpedia, an open encyclopedia
Revision as of 20:49, 22 August 2021 by >DaxServer (Add back cat per discussion WP:TCAT using Pywikibot category add)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Information red.svg
Scan the QR code to donate via UPI
Dear reader, We need your support to keep the flame of knowledge burning bright! Our hosting server bill is due on June 1st, and without your help, Bharatpedia faces the risk of shutdown. We've come a long way together in exploring and celebrating our rich heritage. Now, let's unite to ensure Bharatpedia continues to be a beacon of knowledge for generations to come. Every contribution, big or small, makes a difference. Together, let's preserve and share the essence of Bharat.

Thank you for being part of the Bharatpedia family!
Please scan the QR code on the right click here to donate.

0%

   

transparency: ₹0 raised out of ₹100,000 (0 supporter)



Bharat Immunologicals and Biologicals Corporation
Traded asBSE: 524663
Key people
Sh. Chandra Prakash Goyal
(Managing Director)
ProductsPolio vaccine
OwnerGovernment of India
Websitebibcol.com

Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Public Sector Undertaking (PSU) of the Government of India. Established in 1989 in Bulandshahar, Uttar Pradesh, BIBCOL manufactures oral polio vaccines (OPVs) and other immunisers.[1] The company formulates over 12.5 crore doses of OPV and had aggregated revenues of ₹30.5 crore (equivalent to ₹79 crore or US$11 million in 2019) in fiscal 2006.[2][3]

BIBCOL is under the administrative control of the Department of Biotechnology, Ministry of Science and Technology.

Products[edit]

  1. Diarrhea Management Kit—Diarrhea Management Kit (Zinc Tablet + oral rehydration salts (ORS)) for management of diarrhea among young children.
  2. Oral Polio Vaccine—The live oral polio vaccine (OPV) is a trivalent vaccine containing suspensions of type 1, 2 and 3 attenuated poliomyelitis viruses (Sabin strains) prepared in primary by monkey kidney cell culture.
  3. Zinc Dispersible Tablet—The dispersible zinc tablet, BIBZinC-20 mg contains 20 mg of elemental zinc as active ingredient and contains sweetener and taste masker (Vanilla flavor) and is scored tablet. The product is in line with the recommendations of the WHO. The product is produced with technology transfer from Nutriset through the Department of Biotechnology, Ministry of Science and Technology, Government of India. The Nutriset product has been tested in Indian fields and clinical trials have evaluated the efficacy of zinc supplementation and safety.
  4. IFA Tablets—Iron-deficiency anemia (IDA) is most ignored in developing countries and is the major cause of anemia. The Iron Folic Tablets (IFA Tablets) are a crucial component for treatment of iron deficiency and IDA.

See also[edit]

References[edit]

  1. ↑ "BIBCOL to manufacture 20 million doses of 'covaxin' every month | Web News Observer". 12 May 2021. Retrieved 12 May 2021.
  2. ↑ Company Profile. Department of Biotechnology.
  3. ↑ Financial Statement. Department of Public Enterprise

External links[edit]

Stub icon 1 Stub icon 2

This article about an Indian company is a stub. You can help Bharatpedia by expanding it.

Retrieved from "https://en.bharatpedia.org/index.php?title=Bharat_Immunologicals_and_Biologicals_Corporation&oldid=188583"